Life Sciences

  • June 16, 2026

    Eli Lilly Settles Mounjaro TM Suit Against Seattle Area Clinics

    Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according to a voluntary dismissal motion filed in federal court on Monday, almost two weeks after a judge rejected a resolution proposed by the parties. 

  • June 16, 2026

    Del. Judge Won't Touch Jury's $83M Diagnostics IP Verdict

    A Delaware federal judge on Tuesday upheld a jury's 2023 verdict finding that Guardant Health Inc. should pay TwinStrand Biosciences Inc. $83.4 million for willfully infringing diagnostic patents, refusing to overturn or enhance the award.

  • June 16, 2026

    SEC Settles Insider Trading Suit Against Biotech Investor

    The U.S. Securities and Exchange Commission announced on Tuesday that a Texas-based investor will pay over $240,000 to settle the agency's claims he improperly traded stocks on insider information by buying shares of a public biotech firm ahead of its 2020 merger with a privately held biotechnology company.

  • June 16, 2026

    Cigna Loses Privilege Bid Due To 'Inaccurate, Redundant' Log

    Cigna "improperly asserted privilege" over hundreds of documents that three laboratories sought as part of the discovery process in federal payment litigation in Connecticut, according to a special master appointed by the judge in the consolidated cases.

  • June 16, 2026

    Judge Allows Pfizer, Moderna Defenses In GSK Vax IP Dispute

    A Delaware federal judge on Tuesday permitted Pfizer and Moderna to move ahead with their arguments that GlaxoSmithKline patents the company claims are infringed by the COVID-19 vaccines are unenforceable because of an unreasonable delay in obtaining them.

  • June 16, 2026

    J&J Talc Trial In LA Ends With Deadlocked Jury

    A mistrial was declared Monday by a Los Angeles state judge in a two-month trial over allegations Johnson & Johnson's talc products caused a woman's deadly mesothelioma after the jury deadlocked during deliberations, according to counsel for the plaintiff.

  • June 16, 2026

    Md. Judge Continues Health Case Law Streak With ACA Ruling

    U.S. District Judge Brendan Abell Hurson in Baltimore has been on the bench for less than three years. He's already building an impressive list of healthcare rulings.

  • June 16, 2026

    Pfizer Agrees To Deal To End Depo-Provera MDL

    The plaintiffs in the multidistrict litigation accusing Pfizer of failing to warn consumers of a link between brain tumors and the hormonal contraceptive Depo-Provera have reached an agreement with the pharmaceutical giant, according to an order filed Monday.

  • June 15, 2026

    DOJ Says NY Court Can't Block Texas Trans Records Probe

    The U.S. Department of Justice urged a New York federal court Monday to deny a request for an order barring the government from seeking transgender minor patients' medical records through a criminal subpoena issued by a Texas grand jury, arguing the court lacks jurisdiction.

  • June 15, 2026

    Squires Rejects 7 AIA Cases, Explains Earlier Tesla Decision

    U.S. Patent and Trademark Office Director John Squires has granted five patent challenges and rejected seven others, and he also issued a decision Monday explaining why he allowed a group of Tesla petitions to go ahead to the merits stage of review.

  • June 15, 2026

    Univ. Of Washington Beats Medical Prof's Bias Suit At Trial

    Jurors have cleared the University of Washington's medical school of liability in an anesthesiology professor's lawsuit alleging that she was unfairly ousted from a director role after complaining of discrimination and harassment, finding that the professor failed to sufficiently prove any of her three claims against the school.

  • June 15, 2026

    FTC Pulls OptumRx Insulin Price Case To Review Final Deal

    The Federal Trade Commission's third and final settlement resolving an in-house case accusing pharmacy benefit managers of inflating insulin prices through rebate schemes is in sight after the agency on Friday pulled from adjudication its allegations against UnitedHealth Group Inc.'s OptumRx to review a deal struck with staffers.

  • June 15, 2026

    $239M LabCorp Deal Illegally Shared Genetic Info, Suit Says

    Genetic testing company Invitae Corp. has been hit with proposed class privacy claims by an Illinois parent who says the company unlawfully disclosed its patients' genetic information to LabCorp after the laboratory testing giant bought Invitae out of bankruptcy.

  • June 15, 2026

    CareFirst Says Intent Standard Was Misread In Stelara Case

    CareFirst is arguing that a Virginia federal judge created a new standard for monopolization claims when he dismissed claims from the company's antitrust suit challenging Johnson & Johnson's protection of its immunosuppressive drug Stelara, arguing he misread a Fourth Circuit decision in ruling that monopolization requires a showing of specific intent.

  • June 15, 2026

    Mead Johnson Wins New Trial Over $60M NEC Formula Verdict

    An Illinois appellate panel has thrown out a $60 million jury verdict awarded to a mother claiming Mead Johnson's infant formula caused her premature baby to develop a fatal gut disease, saying the trial court erred in finding the company owed a duty to warn the mother and not just the infant's doctors, and allowing prejudicial evidence about Mead Johnson's profits.

  • June 15, 2026

    Wyo. Judge Nixes 3 Abortion Care Limits As Unconstitutional

    A Wyoming judge has struck down three state laws restricting abortion care, finding that the state failed to demonstrate it had a compelling interest in effectuating a 48-hour waiting period for abortions and requiring certain abortion facilities to be licensed as ambulatory surgical centers, among other restrictions.

  • June 15, 2026

    Nano-X Investors Sue Over Korea Plant Restructuring Hit

    Medical imaging company Nano-X Imaging Ltd. faces a proposed investor class action alleging it failed to tell investors that it had expanded its manufacturing operations beyond what customer demand justified, ultimately leading to a $17.5 million write-down.

  • June 15, 2026

    Hagens Berman Must Cover Fees After Misconduct Findings

    Hagens Berman Sobol Shapiro LLP must cover the fees and costs of a special master who alleged the firm committed misconduct in product liability litigation over the morning sickness drug thalidomide, a Pennsylvania federal judge has said.

  • June 15, 2026

    Mylan Investor Claims Atty Fees Too Much For 'Lost' Case

    An attorney and stockholder in the former Mylan NV objected to the attorneys' fees in a proposed $60 million class action settlement, telling a Pennsylvania federal judge Monday that the plaintiffs' lawyers effectively "lost" a suit that began with allegations of $5.1 billion in lost share value.

  • June 15, 2026

    Judge Gives First OK To $69M ChemoCentryx Deal

    A California federal judge has given the first green light to a $69 million settlement reached between investors and ChemoCentryx, resolving claims that the California-based pharmaceutical company overstated the efficacy of its newly developed treatment for autoimmune disease ANCA vasculitis.

  • June 12, 2026

    Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial

    A Delaware federal jury decided Friday that Amgen Inc. and its Teneobio Inc. unit willfully infringed a mouse antibody patent asserted by Harbour Antibodies BV and others, and should pay $20.2 million in damages — the full amount Harbour was seeking.

  • June 12, 2026

    J&J Trial Over Doctor's Cancer Death Ends In Settlement

    A long-running dispute over whether Johnson & Johnson's baby powder caused the cancer that killed a Miami anesthesiologist concluded with a settlement just before closing arguments in a second trial after the first ended in a hung jury. 

  • June 12, 2026

    Disability Rights Orgs. Seek To Halt NY, Ill. 'Aid-In-Dying' Laws

    Disability rights organizations hit the governors of New York and Illinois with a pair of federal lawsuits seeking to stop new laws in each state from taking effect that would allow patients with terminal illnesses to seek a doctor's assistance in ending their lives.

  • June 12, 2026

    Zoetis Brass Face Derivative Suit Over Pet Meds Statements

    Directors and officers of animal health company Zoetis Inc. have been hit with shareholder derivative claims that they breached their fiduciary duties by concealing that safety warnings about one of its products and increasing competition were hurting the company's bottom line.

  • June 12, 2026

    Insider Trading Defense May Draw On 'Varsity Blues' Playbook

    After enlisting a crew of experienced attorneys, defendants charged in an insider trading case allegedly involving deal information stolen from huge law firms are preparing to use a strategy that could take some cues from the "Varsity Blues" case in the same Boston courthouse.

Expert Analysis

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

  • FDA Guidance May Move Goalposts For Form 483 Responses

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.

  • 2 Strands Of Patent Law In High Court's 'Skinny Label' Case

    Author Photo

    Amarin v. Hikma, which is set for oral argument in the U.S. Supreme Court this month, highlights the distinction between two different strands of intellectual property law — analogizing a patent to either a property deed or a home, says Jonas McDavit at Spencer West.

  • Why MDLs Slow Down — And How To Speed Them Up

    Author Photo

    Multidistrict litigation has become central to mass tort practice, but as MDLs grow in size and complexity, so do delays and costs — so tools like the new federal rule governing MDLs, targeted use of special masters and strategically deployed Lone Pine orders are more essential than ever, say attorneys at Ice Miller.

  • A Check-Up On HHS' Push To Implement AI Infrastructure

    Author Photo

    The U.S. Department of Health and Human Services has made some headway in its efforts to implement artificial intelligence across its agencies, but will have to overcome a number of near-term tests in order to be successful, says Theodore Thompson at Stinson.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.